Blog providing in-depth analysis of key securities & corporate governance litigation issues, and tweeting current developments. Primary author: @DWGreene
Friends, in our latest @WLF Legal Backgrounder, my colleagues Gen York-Erwin and Zach Taylor and I identify 3 key takeaways from the 2nd Circuit’s decision in Bristol-Meyers. #pslra#securitieslitigation https://t.co/UHrZNODI4z
Just discovered this 2017 analysis of biopharma shareholder lawsuits — really interesting! By @DWGreene.
Bottom line is that companies are usually well-protected against these sorts of suits. https://t.co/jaEKYDsqpw
Shout out to my daughter @Sophie4Earth for starting https://t.co/JlOyyUhLNp, which reviews musicals for those on the spectrum or who otherwise have light/sound sensitivities. Thanks @ABrightMonster for your support and encouragement! @Lin_Manuel@BroadwayGirlNYC
Friends, I appreciate https://t.co/mIJ6rwoUjQ blogging about my analysis of the impact of #COVID19 on securities & #corpgov litigation - https://t.co/RZiZ6fjgso Blog @LizDunshee @lynnjokela @JohnJenkins36 #pslra#riskmanagement https://t.co/Cvm7dD4mQX
#COVID19 securities and governance litigation risk will be manageable if public companies, directors, and officers disclose candidly and govern actively. Here are practical tips. https://t.co/lYOOXMjwP0 #CorpGov#riskmanagement
#SCOTUS's Omnicare decision improves corporate disclosure by allowing executives to voice genuinely held opinions without fear of unfair liability. My article for @WLF on Omnicare's 5th anniversary: https://t.co/XMck7ORQ5S #riskmanagement#corpgov#pslra@BakerHostetler
Blue Apron will not eliminate concurrent state-court 1933 Act cases.... The only way ... to improve 1933 Act outcomes is to create a system that results in more effective and efficient litigation defense."
@DandODiscourse#corpgov#riskmanagement#SCOTUS https://t.co/7UekYJDmAB
It was an honor to work with @WLF on its Omnicare #SCOTUS amicus brief. And, on Omnicare’s 5th anniversary, it is gratifying to review the improvement it has made in securities class action—and to know we in the defense bar can make even better use of it. #corpgov#riskmanagement
My new @DandODiscourse post: Blue Apron is not a silver bullet. Companies and their D&O insurers, brokers, and defense counsel need to work together to develop strategies to defend 1933 Act cases more effectively and efficiently. https://t.co/7UekYJDmAB #corpgov#riskmanagement
My new @DandODiscourse post: "The only way [to] achieve better outcomes in 1933 Act cases is to improve the effectiveness and efficiency of securities class action defense. It is that simple. There are no shortcuts." https://t.co/7UekYJDmAB #CorpGov#riskmanagement#pslra
Excellent article by John McCarrick of @WhiteandWil on COVID-19 D&O underwriting issues. Great guidance for public company directors, officers, and lawyers too. https://t.co/oFgQoOaAE8 #corpgov#riskmanagement@kevinlacroix
Securities class action "litigation" is a misnomer; we don't actually litigate securities class actions anymore--to the tremendous detriment of public companies and their directors, officers, and D&O insurers and brokers. ICYMI. https://t.co/pySP0gfl2C #corpgov#riskmanagement
Why do we rarely defend securities class actions past the motion to defense stage anymore? What can we do to fix this systemic problem? I answer these questions & more, ICYMI. https://t.co/pySP0gfl2C #corpgov#riskmanagement#pslra#ClassAction@DandODiscourse
Does the D&O insurance product give public company directors and officers the right protection in today's securities & governance litigation environment? I address this & more in my latest D&O Discourse post. https://t.co/9VkBlejufY #corpgov#riskmanagement#pslra